Patents by Inventor Peter ABBINK

Peter ABBINK has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Recombinant adenoviruses and uses thereof
    Patent number: 11773142
    Abstract: Featured are recombinant adenoviruses and vectors thereof. In particular, the adenoviruses are simian (rhesus) adenoviruses having a low seroprevalence and high immunogenicity (when expressing, e.g., an antigenic polypeptide) relative to other adenoviruses and vectors thereof. Also featured are methods for producing the adenoviruses and methods of treatment of diseases by administering the adenoviral vector(s) to a subject (e.g., a human).
    Type: Grant
    Filed: December 11, 2018
    Date of Patent: October 3, 2023
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Dan H. Barouch, Peter Abbink, Mark Justin Iampietro, Menzo J. E. Havenga
  • RECOMBINANT ADENOVIRUSES AND USES THEREOF
    Publication number: 20200399323
    Abstract: Featured are recombinant adenoviruses and vectors thereof. In particular, the adenoviruses are simian (rhesus) adenoviruses having a low seroprevalence and high immunogenicity (when expressing, e.g., an antigenic polypeptide) relative to other adenoviruses and vectors thereof. Also featured are methods for producing the adenoviruses and methods of treatment of diseases by administering the adenoviral vector(s) to a subject (e.g., a human).
    Type: Application
    Filed: December 11, 2018
    Publication date: December 24, 2020
    Inventors: Dan H. BAROUCH, Peter ABBINK, Mark Justin IAMPIETRO, Menzo J. E. HAVENGA
  • Recombinant adenoviruses and use thereof
    Patent number: 10781427
    Abstract: The present invention relates to recombinant adenoviruses and vectors thereof. In particular, the adenoviruses are novel simian adenoviruses having a low seroprevalence and high immunogenicity relative to other adenoviruses and vectors thereof. The invention also provides methods for production of the adenoviruses and for the treatment of diseases by administering the adenoviral vector(s) to a subject (e.g., a human).
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: September 22, 2020
    Assignees: Beth Israel Deaconess Medical Center, Inc., Washington University
    Inventors: Dan H. Barouch, Herbert Virgin, IV, Peter Abbink
  • Compositions and methods for preventing and treating Zika virus infection
    Patent number: 10611801
    Abstract: The invention relates to immunogenic compositions and vaccines containing a ZIKV protein or a polynucleotide encoding a Zika virus (ZIKV) protein and uses thereof. The invention also provides methods of treating and/or preventing a ZiKV infection by administering an immunogenic composition or vaccine of the invention to a subject (e.g., a human).
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: April 7, 2020
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Dan H. Barouch, Peter Abbink, Rafael Larocca
  • COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING ZIKA VIRUS INFECTION
    Publication number: 20190144506
    Abstract: The invention relates to immunogenic compositions and vaccines containing a ZIKV protein or a polynucleotide encoding a Zika virus (ZIKV) protein and uses thereof. The invention also provides methods of treating and/or preventing a ZiKV infection by administering an immunogenic composition or vaccine of the invention to a subject (e.g., a human).
    Type: Application
    Filed: June 9, 2017
    Publication date: May 16, 2019
    Inventors: Dan H. BAROUCH, Peter ABBINK, Rafael LAROCCA
  • RECOMBINANT ADENOVIRUSES AND USE THEREOF
    Publication number: 20190136205
    Abstract: The present invention relates to recombinant adenoviruses and vectors thereof. In particular, the adenoviruses are novel simian adenoviruses having a low seroprevalence and high immunogenicity relative to other adenoviruses and vectors thereof. The invention also provides methods for production of the adenoviruses and for the treatment of diseases by administering the adenoviral vector(s) to a subject (e.g., a human).
    Type: Application
    Filed: October 12, 2018
    Publication date: May 9, 2019
    Inventors: Dan H. BAROUCH, Herbert VIRGIN, IV, Peter ABBINK
  • Recombinant adenoviruses and use thereof
    Patent number: 10106781
    Abstract: The present invention relates to recombinant adenoviruses and vectors thereof. In particular, the adenoviruses are novel simian adenoviruses having a low seroprevalence and high immunogenicity relative to other adenoviruses and vectors thereof. The invention also provides methods for production of the adenoviruses and for the treatment of diseases by administering the adenoviral vector(s) to a subject (e.g., a human).
    Type: Grant
    Filed: November 15, 2013
    Date of Patent: October 23, 2018
    Assignees: Beth Israel Deaconess Medical Center, Inc., Washington University
    Inventors: Dan H. Barouch, Herbert Virgin, IV, Peter Abbink
  • Replicating recombinant adenovirus vectors, compositions, and methods of use thereof
    Patent number: 9750801
    Abstract: Replicating recombinant adenovirus vectors derived from human adenovirus serotype 26 or human adenovirus serotype 35 are described. The replicating recombinant adenovirus vectors have attenuated replicative capacity as compared to that of the corresponding wild-type adenovirus. They can be used for stable expression of heterologous genes in vivo. Also described are compositions and methods of using these recombinant adenovirus vectors to induce an immune response in a subject, and vaccinate a subject against an immunogenic human immunodeficiency virus (HIV) infection.
    Type: Grant
    Filed: February 26, 2015
    Date of Patent: September 5, 2017
    Assignees: Janssen Vaccines & Prevention B.V., Beth Israel Deaconess Medical Center, Inc.
    Inventors: Dan Barouch, Peter Abbink
  • RECOMBINANT ADENOVIRUSES AND USE THEREOF
    Publication number: 20150291935
    Abstract: The present invention relates to recombinant adenoviruses and vectors thereof. In particular, the adenoviruses are novel simian adenoviruses having a low seroprevalence and high immunogenicity relative to other adenoviruses and vectors thereof. The invention also provides methods for production of the adenoviruses and for the treatment of diseases by administering the adenoviral vector(s) to a subject (e.g., a human).
    Type: Application
    Filed: November 15, 2013
    Publication date: October 15, 2015
    Applicants: WASHINGTON UNIVERSITY, BETH ISRAEL DEACONESS MEDICAL CENTER, INC.
    Inventors: Dan H. Barouch, Herbert Virgin, IV, Peter Abbink
  • REPLICATING RECOMBINANT ADENOVIRUS VECTORS, COMPOSITIONS, AND METHODS OF USE THEREOF
    Publication number: 20150246112
    Abstract: Replicating recombinant adenovirus vectors derived from human adenovirus serotype 26 or human adenovirus serotype 35 are described. The replicating recombinant adenovirus vectors have attenuated replicative capacity as compared to that of the corresponding wild-type adenovirus. They can be used for stable expression of heterologous genes in vivo. Also described are compositions and methods of using these recombinant adenovirus vectors to induce an immune response in a subject, and vaccinate a subject against an immunogenic human immunodeficiency virus (HIV) infection.
    Type: Application
    Filed: February 26, 2015
    Publication date: September 3, 2015
    Inventors: Dan BAROUCH, Peter ABBINK